59 results about "Intestinal villus" patented technology

The invention discloses an application of a pyrrosia lingua aqueous extract in preparation of a medicine for preventing and treating radioactive intestinal injury. Radioactive intestinal injury is a common complication of ionizing radiation, and has main pathological characteristics of intestinal mucosal barrier destruction, excessive release of inflammatory factors, increase of oxidative stress level and hematopoiesis and immune function inhibition. At present, no effective and safe prevention and treatment medicine is available. It is found for the first time that the pyrrosia lingua aqueous extract can inhibit expression (IL-6, TNF-alpha and IL-1beta) of inflammatory factors of radiation-induced MODE-K cells and relieve the oxidative stress level (malondialdehyde (MDA) is reduced, and the content of superoxide dismutase (SOD) and glutathione (GSH) is increased). In animal experiments, the pyrrosia lingua aqueous extract can reduce the levels of TNF-alpha and IL-1beta inflammatory factors in serum of irradiated mice and improve oxidative stress disorders such as MDA increase, SOD and GSH decrease and the like; the reduction of leukocytes and lymphocytes is relieved; the length of intestinal villus is promoted and recovered; the proportion of Ki67 positive cells in a crypt region is increased, so that the regeneration capacity of intestinal epithelial cells is enhanced. The pyrrosia lingua aqueous extract disclosed by the invention provides an experimental basis and an application prospect for developing a novel medicine for preventing and treating the radioactive intestinal injury.

The invention discloses a rapeseed-derived polypeptide capable of relieving injury of vomitoxin to piglet intestines and application of the rapeseed-derived polypeptide. The rapeseed polypeptide provided by the invention is prepared from the following peptide fragments: YLKDPSKF, IVGI, KGFF, GHQYIVT, YYF, FHLY, STFSEY, SVDKQIAK, FYSI and ALRAPLGQN. The rapeseed polypeptide has the advantages that the rapeseed polypeptide is prepared from the following peptide fragments; the method comprises the following steps: extracting rapeseed protein isolate from fat rapeseed dregs, and carrying out enzymolysis, dialysis and ultrafiltration to obtain the micromolecular rapeseed polypeptide with the molecular weight of less than 1kDa. Researches show that the polypeptide can relieve piglet weight loss caused by vomitoxin intestinal injury, can reduce the concentration of proinflammatory factors in serum, and can relieve inflammatory factor infiltration; meanwhile, the rapeseed polypeptide can protect the jejunum tissue of the piglet and reverse jejunum tissue crypt hypertrophy and intestinal villus shortening caused by a DON model group, has an intestinal tissue injury recovery effect, and can be applied to deep processing of rapeseed meal and relieving vomitoxin-induced piglet intestinal injury.

The application provides application of PAI-1 protein in detection and treatment of NEC patients and FNEC patients. The inventor of the application, in combination with years of experience and a large amount of research screening, obtains a biomarker capable of quickly assisting in diagnosis of NEC patients and identifying FNEC patients and Non-FNEC patients, and the biomarker is PAI-1 protein. The PAI-1 protein can be used for auxiliary diagnosis of NEC patients and early screening of FNEC patients, and FNEC patients are identified in time, so that intervention measures are taken in time, and mortality is reduced. Moreover, inhibition of expression of the PAI-1 protein can effectively relieve intestinal villus injury of a NEC model animal, and significantly reduce mortality. Therefore, the PAI-1 protein can be used as a potential target for treating NEC patients, and an agent for inhibiting expression of the PAI-1 protein can be used as a potential drug for treating NEC patients.

The invention discloses an application of Limosilicilla fermentum WMSN-2 in the aspect of preventing neonatal necrotizing enterocolitis, and belongs to the field of application of probiotics. The invention further discloses a preparation method of the Limosilicilla fermentum WMSN-2 for preventing neonatal necrotizing enterocolitis. The lactobacillus mucus WMSN-2 strain provided by the invention has bacteriostatic ability, antibiotic sensitivity and good gastrointestinal fluid tolerance, has the effect of preventing and treating neonatal necrotizing enterocolitis, can reduce the disease activity index of neonatal necrotizing enterocolitis individuals, and can be used for treating neonatal necrotizing enterocolitis. The survival rate is improved; the small intestine shortening and intestinal villus injury are relieved. The lactobacillus mucus WMSN-2 strain provided by the invention can be used for preparing medicines for preventing and treating neonatal necrotizing enterocolitis, can also be used for preparing functional foods and feeds, and has a wide application prospect.

Cryptosporidium parvum is a highly prevalent zoonotic and anthroponotic protozoan parasite that causes a diarrheal syndrome in children and neonatal livestock, culminating in growth retardation and mortalities. Disclosed herein are inhibitors against the enzymatic activity of recombinant CpLDH protein that were identified. The inhibitors were tested for anti-Cryptosporidium effect using in vitro infection assays of HCT-8 cells monolayers. Compounds NSC158011 and NSC10447 were identified to inhibit the proliferation of intracellular C. parvum in vitro, with IC50 values of 14.88 and 72.65 μM, respectively. At doses tolerable in mice, both NSC158011 and NSC10447 significantly reduced the shedding of C. parvum oocysts in infected immunocompromised mice's feces and prevented intestinal villous atrophy as well as mucosal erosion due to C. parvum. These findings have unveiled anti-Cryptosporidium drug candidates that can be explored further for the development of therapeutic agents against C. parvum infections.

The present invention discloses an adaptive enhancement method for endoscopic images, which belongs to the interdisciplinary technical field of combining computer vision and medicine. The present invention uses a guided filter to filter the endoscopic image to obtain a low-frequency component with good edge and gradient preservation, and constructs an illumination gain function based on the low-frequency components of different regions of the image to adaptively generate an illumination gain factor; and constructs a gradient gain function based on the Laplace operator convolution results of different regions of the endoscopic image to adaptively generate a gradient gain factor; finally, the illumination gain factor and the gradient gain factor are combined to generate the adaptive gain coefficient required by the USM method to complete the improvement of the USM method. Experiments have shown that when the present invention is applied to the enhancement of small intestinal endoscopy images, it can effectively enhance the detail information of the small intestinal villi while suppressing the dark area noise and preventing the edge overshoot phenomenon, effectively highlighting the edge detail information with tiny villi structure.

This invention relates to the field of feed additive technology, specifically to a feed additive that promotes digestion and absorption and its preparation process. The preparation process of a feed additive that promotes digestion and absorption includes: preparing antioxidant-modified chicken fat; preparing an extract; preparing a composite oil phase; and preparing the feed additive. In this invention, the extract of Shenqu (a type of fermented wheat) can directly compensate for insufficient endogenous enzyme secretion in laying hens, rapidly decomposing starch in feed and chicken fat in plant proteins, laying the foundation for subsequent absorption. The extract of Zhishi (a type of immature bitter orange) accelerates gastrointestinal motility and digesta emptying, while also promoting bile and pancreatic juice secretion, further improving the digestibility and utilization rate of fat-soluble components in laying hens. The extract of pine pollen can repair the intestinal mucosa, increase intestinal villus height, increase the nutrient absorption area, and regulate the intestinal microecology, reducing nutrient loss and intestinal stress. The combined use of these three ingredients synergistically promotes the digestive and absorptive capacity of laying hens.

The present invention provides an application of a composition in the preparation of a product for improving intestinal development; the composition comprises 1 to 10 parts by weight of whey protein powder rich in milk fat globule membrane and 1 part by weight of whey protein powder rich in caseinoglycomacropeptide. The composition of whey protein powder rich in milk fat globule membrane and whey protein powder rich in caseinoglycomacropeptide with a mass ratio of (1-10):1 provided by the present invention has a synergistic effect on promoting intestinal development and can significantly increase the villus height of the intestine and the intestinal villus crypt ratio.

A use of a flavonoid compound and a drug for preventing and / or treating familial intestinal polyposis. In the present invention, it is found for the first time by experiments that the compound as shown in formula I can correct the disorder of β-catenin accumulation in cell nuclei caused by APC gene mutation to promote the transfer of β-catenin to cell membranes, can promote the restoration of the normal morphology of intestinal villi with dysplasia and deformity, and can decrease the number of intestinal polyps caused by APC mutation, thereby achieving the effect of preventing and treating familial intestinal polyposis.

The application discloses a kind of for radiation intestinal injury treatment composition and its application, it is related to medical technical field.The composition includes the following components: aesculetin, fraxinol, fraxin and baicalein.The composition of the application can reduce intestinal villus injury by regulating the NF-κB pathway and Caspase-9 / 3 pathway of intestinal epithelial cells, reduce the infiltration of intestinal inflammatory cells, reduce intestinal cell apoptosis, to relieve intestinal injury, and then multi-component, multi-pathway jointly play the efficacy of treating radiation intestinal injury.The application solves the problem that there is no effective drug for treating radiation intestinal injury in the prior art.

The invention discloses application of oxidized berberine and neohesperidin in improving intestinal health of broiler chickens, and belongs to the technical field of feed additives. Research finds that oxidized berberine and neohesperidin can increase the intestinal villus height, crypt depth and goblet cell number of broiler chickens and improve intestinal health; the slaughter indexes such as daily weight gain and feed intake can be improved, the feed-weight ratio is reduced, and the slaughter indexes such as carcass weight and semi-eviscerating weight are increased; meanwhile, the serum immune factor and antioxidant index level is improved, the safety is high, and no obvious toxicity exists; and the two components are combined for use, so that a synergistic interaction effect is also achieved. The invention provides a new raw material resource for improving the intestinal health of the broiler chicken and improving the production performance and economic value of the broiler chicken.

The invention discloses a method for detecting fish gelatin protein based on Cu-MOF (at) PDA (at) PBA and bionic intestinal villus micro-tissues, and belongs to the technical field of electrochemical sensors and food safety detection. The preparation method comprises the following steps: taking polydopamine modified Cu-MOF as a substrate to preliminarily fix template molecules, and taking 3, 5-difluorophenylboronic acid as a functional monomer to form Cu-MOF (at) PDA (at) PBA / MIPs; then adding the conductive hydrogel, mast cells and endothelial cells into a methacrylated gelatin solution to prepare conductive hydrogel; carrying out 3D printing on the bionic small intestine villus micro-tissue; adhering the bionic intestinal villus micro-tissue to a PDMS (Polydimethylsiloxane) base electrode to obtain a hydrogel electrode; then, by taking the hydrogel electrode as a working electrode, establishing a three-electrode system, and constructing an electrochemical bionic intestinal villus micro-tissue sensor; and finally detecting the fish gelatin protein, wherein the detection limit is as low as 0.051 ng / mL.

This invention discloses a strain of *Bacillus belyceae* with broad-spectrum antibacterial activity and its application in the prevention and treatment of necrotic enteritis in poultry. The *Bacillus belyceae* strain provided by this invention (… Bacillus from Velez The genome of strain GDG25CB056 is approximately 3.91 Mb in size, contains no virulence factors, and is rich in gene clusters encoding non-ribosomal peptides and polyketide synthases. Studies have confirmed that this strain exhibits significant growth advantages, strong tolerance to high temperatures, gastric acid, and bile salts, which facilitates intestinal colonization. It can produce siderophores and various enzymes, and has overcome the technical bottleneck of a narrow antibacterial spectrum, possessing broad-spectrum antibacterial activity, especially strong specific antagonistic activity against Clostridium perfringens. In vivo experiments have shown that this strain can significantly reduce the Clostridium perfringens load in the cecum of chicks with necrotizing enterocolitis, alleviate intestinal congestion and swelling, repair damaged intestinal villi, and enhance mucosal barrier function, providing a safe and efficient strain resource for the prevention and treatment of bacterial enteric diseases.

The invention discloses application of indole-3-acetaldehyde and salt thereof in a product for repairing animal intestinal injury, relates to the technical field of animal intestinal injury repairing, and aims to improve animal intestinal injury induced by vomitoxin. Animal experiments prove that after being treated by a product containing indole-3-acetaldehyde, the vomitoxin-induced intestinal injury degree can be remarkably reduced, the activity of intestinal stem cells can be remarkably improved, the villus height and permeability in intestines can be improved, proliferation and differentiation of the intestinal stem cells can be promoted, and the proliferation level of intestinal epithelial cells can be improved. A new thought can be provided for research and development of products for repairing the vomitoxin-induced intestinal injury, and a new nutrition regulation and control means can be developed for treating the vomitoxin-induced intestinal injury.

The application belongs to the technical field of organ chip models, and specifically discloses a liver-intestine chip model and a method for evaluating the influence of oligosaccharides on the liver by using the same. The liver-intestine chip model comprises a multilayer microfluidic structure, the main body material of the multilayer microfluidic structure is modified polydimethylsiloxane, the multilayer microfluidic structure comprises an intestinal microcavity, a liver microcavity and a microchannel connecting the two, the intestinal microcavity is inoculated with intestinal epithelial cells, the liver microcavity is inoculated with liver cells, the bottom of the liver microcavity is provided with a window array, the corner of the liver microcavity is provided with a groove, the bottom of the intestinal microcavity is integrated with an elastic membrane, the elastic membrane is communicated with an external air pressure driving system, and the upper surface of the elastic membrane is etched with a microstructure similar to small intestinal villi. By using the above liver-intestine chip model and the method for evaluating the influence of oligosaccharides on the liver by using the same, the liver-intestine organ chip model can simulate the microenvironment of the intestinal-liver axis in vivo, and provides a more real and reliable platform for studying the influence of oligosaccharides on the liver.

Provided in the present disclosure is a strain of Lacticaseibacillus rhamnosus DY801 and an application thereof. The Lacticaseibacillus rhamnosus DY801 is deposited in the Guangdong Microbial Culture Collection Center (GDMCC) on Oct. 9, 2022, with a deposit number of GDMCC 62853. The Lacticaseibacillus rhamnosus DY801 provided by the present disclosure may inhibit oxidative stress in the intestinal tract and damage to the small intestinal villi under radiotherapy and chemotherapy conditions by producing a large amount of glutathione in order to reduce inflammatory cytokines, which is also tolerant to artificial gastric and intestinal fluids, and has no obvious toxic side effects on the human body, providing a high level of safety.

The invention discloses application of dryopteris fragrans polysaccharide in treatment of chronic lead poisoning, and belongs to the technical field of biology. The invention aims at solving the technical blank of application of dryopteris fragrans polysaccharide in chronic lead poisoning and solving the technical problems of complicated operation, low polysaccharide retention rate and low polysaccharide purity of a polysaccharide extraction and purification method in the prior art. According to the method for extracting and purifying the dryopteris fragrans polysaccharide, pigments and residual protein in the dryopteris fragrans polysaccharide can be effectively removed, the effect of reducing the deproteinization treatment frequency is achieved, the decolorization rate reaches 78.76%, the polysaccharide retention rate is high, and the method can be used for industrially producing the dryopteris fragrans polysaccharide. The dryopteris fragrans acidic polysaccharide obtained through the extraction and purification method can be applied to treatment of chronic lead poisoning, so that the purpose of reducing growth delay, liver and kidney injury and intestinal villus lesion caused by chronic lead poisoning is achieved.

The invention provides a plant lactobacillus MLPCO23 resistant to PEDV (porcine epidemic diarrhea virus) infection and application of the plant lactobacillus MLPCO23, and belongs to the technical field of microorganisms. The preservation number of the plant lactobacillus MLPCO23 is CCTCC (China Center for Type Culture Collection) NO: M 20252370. The plant lactobacillus MLPCO23 can be colonized in intestinal tracts, has a remarkable PEDV (porcine epidemic diarrhea virus) resisting effect, and can be used for improving the PEDV infection resisting capability of piglets and relieving clinical symptoms caused by PEDV infection. The plant lactobacillus MLPCO23 can repair intestinal villi and close connection structures, increase the number of goblet cells and maintain the steady state of intestinal barriers. The plant lactobacillus MLPCO23 serving as intestinal probiotics provides a new intervention target and a prevention and control strategy for PEDV infection, and also provides a new thought and a new clue for clarification of the effect and mechanism of Min pig flora for regulating intestinal mucosa microecology and resisting PEDV infection.

The invention provides application of ergothioneine in improving growth of large yellow croakers in a wintering period, improving liver oxidation resistance and enriching intestinal flora, and belongs to the technical field of aquaculture. According to the method, 25 mg / kg and 50 mg / kg of ergothioneine are added into feed for the larimichthys crocea juvenile fish in the wintering period for feeding, and results show that the ergothioneine can remarkably improve the weight gain rate, the specific growth rate and the muscle and whole fish crude fat content of the larimichthys crocea juvenile fish; the activity of CAT, T-SOD and GSH-Px in the liver of a test group is remarkably improved, and the content of MDA is remarkably reduced; in addition, the ergothioneine can improve the intestinal villus height of the larimichthys crocea juvenile fish in the wintering period and improve the abundance of intestinal flora, the abundance of harmful bacteria is reduced, and the abundance of beneficial bacteria is increased. The invention proves that the ergothioneine can promote the growth of the larimichthys crocea juvenile fish in the wintering period, enhance the oxidation resistance and improve the intestinal health, and can be used as a green feed additive for the larimichthys crocea in the wintering period.

The invention provides application of PAI-1 protein in detection and treatment of NEC patients and FNEC patients. The inventor of the invention combines years of experience and a large amount of research screening to obtain a biomarker capable of rapidly assisting in diagnosis of NEC patients and identifying FNEC patients and Non-FNEC patients, and the biomarker is PAI-1 protein. The PAI-1 protein can be used for auxiliary diagnosis of NEC patients and early screening of FNEC patients, and the FNEC patients can be recognized in time, so that intervention measures are taken in time, and the death rate is reduced. In addition, by inhibiting the expression of the PAI-1 protein, intestinal villus injury of NEC model animals can be effectively relieved, and the death rate is remarkably reduced. Therefore, the PAI-1 protein can be used as a potential target spot for treating the NEC patient, and a reagent for inhibiting the expression of the PAI-1 protein can be used as a potential medicine for treating the NEC patient.

The present invention provides a method and device for identifying atrophy and blunting of small intestinal villi in inflammatory bowel disease, the method comprising: performing edge detection on a grayscale image of a pathological section of small intestinal villi, and enhancing the weak edge to a strong edge when the possibility that the weak edge obtained by edge detection is the edge of the small intestinal villi is greater than a preset possibility threshold; determining the strong edge as the edge of the small intestinal villi when the distance between the strong edge and the background area of ​​the grayscale image is less than a preset distance threshold and the strong edge is not closed; calculating the average length and average width of the small intestinal villi based on the edge of the small intestinal villi, and determining whether the small intestinal villi are atrophied and blunted according to the average length and average width of the small intestinal villi. The present invention enhances the weak edge that may be the edge of the small intestinal villi by the degree of curvature and the degree of difference of the weak edge, thereby more accurately identifying the edge of the small intestinal villi to detect whether the edge of the small intestinal villi is atrophied and blunted.

The present invention discloses the application of rhodotorula ZTHY2 in improving the carcass traits of Leizhou black duck and promoting intestinal health, and belongs to the technical field of poultry breeding. The present invention verifies through experiments that rhodotorula ZTHY2 can improve its muscle quality, enhance the nutritional value and flavor level of the muscle; rhodotorula ZTHY2 can also regulate the composition structure and stability of intestinal flora, increase the relative abundance of beneficial flora while inhibiting the proliferation of harmful flora, effectively reduce intestinal permeability, promote the development of intestinal villi, improve intestinal tissue structure, and thus maintain intestinal health. The addition amount of rhodotorula ZTHY2 in feed is 2×10 9 The effect is best when the content of CFU / kg. The invention conforms to the development trend of "antibiotic-free feed" and has important significance for the green, safe and sustainable development of the breeding industry.

The invention discloses a medical application of phellinus igniarius in a medicine for inhibiting the activity of cryptosporidium parvum FBA, provides a medical application of phellinus igniarius in a medicine for inhibiting the activity of cryptosporidium parvum FBA, and discloses that phellinus igniarius can inhibit the activity of rC.pFBA, destroy the normal form of sporozoites, reduce the glycolysis level of sporozoites and relieve the infection of cryptosporidium parvum. The composition can relieve intestinal pathologic symptoms including intestinal villus shortening and erosion, recover the expression quantity of intestinal barrier related proteins and inflammatory factor level, reduce oocyst discharge and the like, and can be prepared into medicines for resisting cryptosporidium parvum.

The invention relates to lactobacillus amylovorans and an application thereof in intestinal diseases, the lactobacillus amylovorans (LA) is named as lactobacillus amylovorans QC1H, is preserved in China Center for Type Culture Collection on March 28, 2023, and has a preservation number of CCTCC NO: M2023427, the lactobacillus amylovorans and / or a fermentation product thereof can significantly improve the ratio of mouse intestinal villus length to crypt depth, and the lactobacillus amylovorans and / or the fermentation product thereof can significantly improve the intestinal villus length and crypt depth of mice. The compound has the advantages of reducing mouse ileum enteritis factor expression, improving ileum tight junction protein expression and reducing intestinal permeability, and has important application significance and value in preparation of a therapeutic agent for preventing and treating enteritis caused by aflatoxin B1 (AFB1).

The invention discloses edible and herbal tea polysaccharide, a preparation method thereof and application of the edible and herbal tea polysaccharide in preparation of a medicine for treating diabetes mellitus. The edible and herbal tea polysaccharide consists of arabinose, galactose and glucose in a molar ratio of 4: 5: 10, and the molecular weight of the edible and herbal tea polysaccharide is 637.5 kD. The research finds that the edible and herbal tea polysaccharide can effectively improve the glucose tolerance and serum TG, TC, HDL-C and LDL-C levels of alloxan mice; the conditions of intestinal villus edema and shedding of an alloxan mouse can be effectively relieved, and the expression level of Occludin, Claudin-1, ZO-1, TNF-alpha, IL-1beta, IL-6, MPO and NF-kappa B pathway related proteins in colon tissues of the alloxan mouse can be effectively recovered; the herbal tea polysaccharide has a good curative effect on diabetes mellitus and enteritis complicated by diabetes mellitus, and a new treatment approach is provided for diabetes mellitus and enteritis complicated by diabetes mellitus.

The invention discloses enterococcus faecium for promoting intestinal tissue repair of aquatic animals and application of the enterococcus faecium, and relates to the technical field of aquaculture, the strain is named as GCE-2, the Latin name is Enterococcus faecium, the strain is preserved in the China General Microbiological Culture Collection Center on January 7, 2026, and the preservation number is CGMCC NO.37319. The invention further discloses a preparation method of the enterococcus faecium capable of promoting intestinal tissue repair of the aquatic animals and application of the enterococcus faecium capable of promoting the intestinal tissue repair of the aquatic animals. The enterococcus faecium GCE-2 provided by the invention can efficiently promote the repair of intestinal tissues of aquatic animals, has relatively strong intestinal colonization ability and good environmental adaptability, and can directly promote the regeneration of intestinal villus and the repair of epithelial cell injury, quickly relieve the pathological symptoms of intestinal tracts and remarkably improve the repair efficiency of the intestinal tissues.

The invention relates to application of a CXCL14 recombinant protein in preparation of a medicine for preventing or treating radiation enteritis, and belongs to the technical field of biomedicine. Excessive inflammation is inhibited by regulating chemotaxis and pro-inflammatory polarization of key immune cells such as macrophages. The CXCL14 recombinant protein directly acts on intestinal epithelial cells and crypt stem cells to promote intestinal villus repair and crypt regeneration, so that the intestinal barrier is structurally recovered. The specific value of intestinal villus length / crypt depth is remarkably increased, and it is proved that the CXCL14 recombinant protein can achieve functional healing instead of symptom relieving.

The invention provides application of astaxanthin in preparation of medicines for preventing and treating intestinal dysfunction and intestinal flora imbalance related to severe acute pancreatitis or repairing intestinal mucosal barrier. In-vivo experiments prove that the astaxanthin can significantly improve SAP-induced intestinal barrier injury, reduce the activity of serum diamine oxidase (DAO), repair a jejunum villus structure and up-regulate the expression of tight junction proteins (ZO-1, Occludin and Claudin); the mechanism relates to inhibition of local inflammatory response and oxidative stress, and specific correction of intestinal flora disorder, including recovery of proportion balance of phylum firmicalis and bacteroides, and improvement of abundance of beneficial bacteria such as lactobacillus murine and ruminococcus; the invention provides a new strategy for clinical treatment of SAP complicated with intestinal failure.

The present invention discloses the application of Oocystis borgei in repairing the microecological imbalance of fish intestines, especially in the preparation of products for repairing the microecological imbalance of fish intestines caused by antibiotics. In the present invention, Oocystis borgei is used as a rapid repair product for the microecological imbalance of fish intestines caused by antibiotics, and its functions include: rapidly restoring the structure and function of the fish intestinal microbial community, promoting the restoration of the composition of resistance genes in the intestinal microbial community, restoring the length of fish intestinal villi, and regulating the expression of genes related to apoptosis and proliferation in fish intestines to achieve rapid repair of the microecological imbalance of fish intestines caused by antibiotics. When Oocystis borgei is prepared into a product with a rapid repair effect on the microecological imbalance of fish intestines caused by antibiotics, it has good application prospects. As a rapid repair product for the microecological imbalance of fish intestines caused by antibiotics, Oocystis borgei functions include: rapidly restoring the structure and function of the fish intestinal microbial community, promoting the restoration of the composition of resistance genes in the intestinal microbial community, restoring the length of fish intestinal villi, and regulating the expression of genes related to apoptosis of fish intestinal villi, the expression of genes related to proliferation of fish intestinal villi, and the expression of genes related to the inhibition of fish intestinal inflammatory response to achieve rapid repair of the microecological imbalance of fish intestines caused by antibiotics.

This invention belongs to the field of microbiology technology, and specifically relates to the application of a strain of *Lactobacillus suis* HL1 derived from wild boars in Xinjiang and its feed additives. Lactobacillus saerimneri HL1, with accession number CGMCC No. 34386. This invention relates to *Lactobacillus suis* HL1, which exhibits good tolerance, strong antioxidant capacity, and effective antibacterial properties. It is sensitive to multiple antibiotics and promotes growth and development, enhancing intestinal villi growth, increasing nutrient absorption, and improving coat luster. This application isolates a potentially beneficial *Lactobacillus* strain with low or no drug resistance from wild boars in Xinjiang and evaluates its in vivo safety, laying the foundation for animal feed additives.